Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine.

Angela T H KwanGia Han LeZiji GuoFelicia CebanKayla M TeopizTaeho Greg RheeRoger HoJoshua D Di VincenzoSebastian BadulescuShakila MeshkatBing CaoJoshua D RosenblatDonovan A DevLee PhanMehala SubramaniapillaiRoger S McIntyre

Published in: Annals of general psychiatry (2024)

NCT05047952 (ClinicalTrials.gov; Registration Date: September 17, 2021).

Keyphrases

coronavirus disease
sars cov
major depressive disorder
oxidative stress
respiratory syndrome coronavirus
bipolar disorder